• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 3. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 4. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 5. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers

Research Briefing on N-{2-(difluoromethoxy)phenylmethylidene}hydroxylamine (CAS: 332110-52-8) in Chemical Biology and Pharmaceutical Applications

N-{2-(difluoromethoxy)phenylmethylidene}hydroxylamine (CAS: 332110-52-8) has recently emerged as a compound of significant interest in chemical biology and pharmaceutical research. This compound, characterized by its unique difluoromethoxy and phenylmethylidene hydroxylamine moieties, exhibits promising pharmacological properties, particularly in the context of enzyme inhibition and drug discovery. Recent studies have focused on elucidating its mechanism of action, synthetic pathways, and potential therapeutic applications, positioning it as a valuable candidate for further investigation.

One of the key areas of research involving 332110-52-8 is its role as a selective inhibitor of specific enzymes involved in inflammatory and oncogenic pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound effectively targets and modulates the activity of certain kinases, which are critical in signal transduction processes. The study highlighted its high binding affinity and selectivity, suggesting potential applications in developing targeted therapies for cancers and autoimmune diseases. Furthermore, the compound's stability and bioavailability were noted as advantageous properties for further drug development.

In addition to its inhibitory properties, N-{2-(difluoromethoxy)phenylmethylidene}hydroxylamine has been investigated for its synthetic versatility. Researchers have developed novel methodologies for its preparation, emphasizing green chemistry principles to enhance yield and reduce environmental impact. A recent publication in Organic Letters detailed a catalytic asymmetric synthesis route, which not only improves the efficiency of production but also opens avenues for the creation of enantiomerically pure derivatives with potentially enhanced biological activities.

The pharmacological potential of 332110-52-8 extends beyond enzyme inhibition. Preliminary in vivo studies have shown that this compound exhibits anti-inflammatory and neuroprotective effects, making it a candidate for treating neurodegenerative disorders such as Alzheimer's disease. A 2024 study in ACS Chemical Neuroscience reported that the compound reduces oxidative stress and amyloid-beta aggregation in neuronal cells, providing a dual mechanism of action that could be leveraged in future therapeutic strategies. These findings underscore the compound's multifaceted utility in addressing complex medical conditions.

Despite these promising developments, challenges remain in the clinical translation of N-{2-(difluoromethoxy)phenylmethylidene}hydroxylamine. Issues such as pharmacokinetic optimization, toxicity profiling, and scalable synthesis need to be addressed to advance this compound into preclinical and clinical trials. Collaborative efforts between academic institutions and pharmaceutical companies are essential to overcome these hurdles and fully realize the therapeutic potential of 332110-52-8.

In conclusion, N-{2-(difluoromethoxy)phenylmethylidene}hydroxylamine (CAS: 332110-52-8) represents a compelling area of research in chemical biology and drug discovery. Its unique chemical structure, combined with its diverse biological activities, positions it as a promising candidate for further development. Continued research into its mechanisms, synthetic improvements, and therapeutic applications will be critical in harnessing its full potential for medical advancements.

• 842168-93-8(Benzaldehyde, methoxy-, oxime)
• 556016-57-0(N-{4-(difluoromethoxy)phenylmethylidene}hydroxylamine)
• 29577-53-5(2-Methoxybenzaldehyde Oxime)
• 31874-34-7(2,4-Dimethoxybenzaldoxime)
• 34967-19-6(N-(2,5-dimethoxyphenyl)methylidenehydroxylamine)
• 139995-93-0(Benzaldehyde, 2-phenoxy-, oxime)
• 150162-39-3(4-(Trifluoromethoxy)benzaldoxime)
• 54582-20-6(Benzaldehyde, 2-methoxy-, oxime, (E)-)
• 51903-38-9((E)-N-(2,4,6-trimethoxyphenyl)methylidenehydroxylamine)
• 174966-94-0((E)-N-[(2,6-dimethoxyphenyl)methylidene]hydroxylamine)